作为抗凝固剂的新型基于triazole的人类因子XIIa的强效抑制剂
Ma'Lik D Woodland1, Anthony Thompson2, Amanda Lipford2
1Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana 70125, United States.
ACS omega
|March 11, 2024
概括
新型三醇化合物8和22有效抑制XIIa因子 (FXIIa),这是血液凝固中的关键酶. 这些强效和选择性抑制剂为治疗血栓栓塞性疾病的更安全的抗凝固疗法提供了一个有希望的新途径.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- XIIa因子 (FXIIa) 是接触激活通路中的血蛋白质酶,涉及到血栓栓塞性疾病.
- 缺乏FXIIa不会影响血液静止,这表明抑制FXIIa可能比目前的治疗方法提供更安全的抗凝固作用.
- 针对人类FXIIa的有限的小分子抑制剂存在,突出显示了对新治疗剂的需求.
研究的目的:
- 确定人类FXIIa的新型小分子抑制剂.
- 评估基于三醇的化合物的功效和选择性,以对抗FXIIa.
- 探索潜在的新型抗凝剂,用于治疗血栓栓塞性疾病.
主要方法:
- 通过染色基质测定,对32种三醇和三醇类分子的库进行了FXIIa抑制活性选.
- 对相关的血清蛋白酶 (FXIa,Xa,IXa) 和血栓激素进行了抑制活性和选择性的评估.
- 在试验室中,使用激活的部分血栓形成时间 (aPTT) 和前血栓时间 (PT) 试验来评估抗凝剂效应.
主要成果:
- 最初的查发现了4个强大的FXIIa抑制剂从18个测试分子在200μM.
- 化合物8显示显著的FXIIa抑制和对FXIa,Xa和IXa的选择性,但也抑制了血栓.
- 结构-活性关系研究产生了亚微分子抑制剂,其中化合物22表现出明显的选择性超过FXIa,Xa,IXa和血栓.
结论:
- 新型基于三醇的小分子,特别是化合物8和22,被确定为人类FXIIa的强有力的抑制剂.
- 化合物22具有显著的选择性,使其成为进一步开发的有希望的候选人.
- 这些发现支持FXIIa抑制剂作为更安全,更有效的血栓栓塞性疾病治疗策略的推进.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994
Antihypertensive Drugs: Thiazide-Class Diuretics
632
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
632


